NOW RECRUITING: A Phase 2 Study to evaluate the safety, tolerability and efficacy of cell transfer therapy using autologous tumor infiltrating lymphocytes (LN-145-04) followed by IL-2 in patients with recurrent and/or metastatic cervical carcinoma.
Key eligibility criteria:
• Measurable metastatic disease and ≥ 1 lesion resectable for TIL generation
• At least one prior systemic therapy
• Age ≥ 18
• ECOG PS 0-1
Endpoints: Safety and Efficacy